Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. (Q51051063)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609470%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609470%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609470%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Boe Sandahl Sorensen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609470%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Anne E Lykkesfeldt

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609470%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Mathilde S Larsen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609470%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Christina W Yde

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609470%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

English

0 references

publication date

23 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609470%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609470%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

139

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609470%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609470%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

71-80

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609470%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10549-013-2485-2

29 February 2020

exact match

0 references

cites work

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Biological determinants of endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

New strategies in estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Mechanisms of endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Endocrine-responsive breast cancer and strategies for combating resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Endocrine therapy--current benefits and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Phosphorylation of the human estrogen receptor by mitogen-activated protein kinase and casein kinase II: consequence on DNA binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2

Deconstructing repression: evolving models of co-repressor action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2485-2